FDA panels put silicone breast implants back under microscope

Key points
- Makers of silicone breast implants have not followed up on thousands of women who received them as required by the Food and Drug Administration as a condition of approval, agency advisers said Wednesday.
- Mentor Worldwide and Allergan Incorporated received FDA approval for their silicone gel-filled breast implants in 2006 after agreeing to do large, 10-year post-market studies.
- Mentor's study enrolled more than 40,000 patients but after three years had a follow-up rate of only 21%.
- Christopher Allman, a spokesperson for Mentor, said since launching the post-approval studies, the company has stressed the importance of follow-up to both the women participating and their doctors.
Makers of silicone breast implants have not followed up on thousands of women who received them as required by the Food and Drug Administration as a condition of approval, agency advisers said Wednesday.
Mentor Worldwide and Allergan Incorporated received FDA approval for their silicone gel-filled breast implants in 2006 after agreeing to do large, 10-year post-market studies. But in a two-day meeting to update two FDA panels on the status of those trials, the companies admitted they had lost track of large numbers of women after implantation.
Mentor's study enrolled more than 40,000 patients but after three years had a follow-up rate of only 21%. Allergan enrolled more than 39,300 women with a follow-up rate of 60% after two years.
Christopher Allman, a spokesperson for Mentor, said since launching the post-approval studies, the company has stressed the importance of follow-up to both the women participating and their doctors. He says it remains a challenge.
"At Mentor's request, letters from FDA were sent to physicians and patients to encourage follow-up and state the importance of follow-up; unfortunately, there was minimal impact with respect to the follow-up rate," Allman said. "We continue to encourage women to participate in these studies.
"Typically, it is not standard of care for breast implant patients to visit their plastic surgeon annually. Patients most likely to follow up with their physician are those who experience complications."
During an open public comment session, some patients and patient advocates told of the horrors they've encountered with silicone implants, in some cases imploring the manufacturers to make sure future studies are well-designed and protect women.
Susan Dorsey from Mount Juliet, Tennessee, replaced her saline implants with silicone six years ago and enrolled in Allergan's study. She said her symptoms began within months.
"I had difficulty raising my arms over my head, I had flu-like symptoms, neck and shoulder pain that resulted in physical therapy three times a week," Dorsey said. "Blurry vision, tingling, loss of appetite, insomnia, joint pain, anxiety, dizziness. Every day seemed to bring new symptoms."
Carolyn Wolfe of Virginia had her implants for 28 years and says she had multiple symptoms. Three years ago she was found to have connective tissue disease, chronic fatigue, chronic obstructive pulmonary disease, asthma and irritable bowel syndrome. An MRI revealed 20 lesions on her brain and two collapsed implants with very little silicone left inside. She had them removed.
"Is the FDA willing to publicly state that silicone and platinum leaking into women's bodies year after year is safe?" she asked panelists.
In contrast, Nicole Noel told the panel she would again get silicone implants after the birth of her second child. "After having two children I had lost all volume. I had no breast tissue. I have more self-confidence and am more proportional."
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsUK agency nearer backing new breast cancer drugs
Britain's cost-effectiveness watchdog NICE came one step closer on Friday to approving a new class of breast cancer treatments known as aromatase inhibitors. The decision by the National Institute of Health and Clinical…
12 August 2006
NewsBreast cancer survivors turning their backs on recommended mammograms
A new study finds use of annual mammography among breast cancer survivors, who are at increased risk of a recurrence or a new malignancy in the other breast, dropped off after a few years. During the five year study…
25 April 2006
NewsNo cancer risk seen with breast implants
Cosmetic breast implants do not seem to increase the risk of cancer, according to the results of a population-based study with more than 15 years of follow-up. A slightly elevated risk of lung cancer was noted in…
19 April 2006



